Issue 3, 2011

Novel indolizine compounds as potent inhibitors of phosphodiesterase IV (PDE4): structure–activity relationship

Abstract

A series of novel indolizine 2-oxoacetamides were designed and synthesized as PDE4 inhibitors. Preliminary SAR of this new class of compounds revealed key structural features required for high potency. Compounds 1ab and 2a are among the most potent inhibitors of PDE4 with low single nM IC50. Cellular activity was demonstrated by the inhibition of TNFα production from human PBMC with IC50 ranging from 14 to 72 nM. Docking analyses suggest the OH group in 1ab enhance the binding via an H-bond interaction with the PDE4 enzyme.

Graphical abstract: Novel indolizine compounds as potent inhibitors of phosphodiesterase IV (PDE4): structure–activity relationship

Article information

Article type
Concise Article
Submitted
12 Nov 2010
Accepted
06 Dec 2010
First published
22 Dec 2010

Med. Chem. Commun., 2011,2, 176-180

Novel indolizine compounds as potent inhibitors of phosphodiesterase IV (PDE4): structure–activity relationship

S. Chen, Z. Xia, M. Nagai, R. Lu, E. Kostik, T. Przewloka, M. Song, D. Chimmanamada, D. James, S. Zhang, J. Jiang, M. Ono, K. Koya and L. Sun, Med. Chem. Commun., 2011, 2, 176 DOI: 10.1039/C0MD00215A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements